Xeris Biopharma Holdings

NasdaqGS:XERS Stock Report

Mkt Cap: US$179.5m

Xeris Biopharma Holdings Management

How experienced are the management team and are they aligned to shareholders interests?

1.1yrs

Average management tenure


CEO

Paul Edick (66 yo)

1.83yrs

Tenure

US$3,764,134

Compensation

Mr. Paul R. Edick serves as the Chief Executive Officer of Xeris Biopharma Holdings, Inc. since May 2021 in connection with the Strongbridge acquisition and has been its Chairman since 2021. He served as P...


CEO Compensation Analysis

How has Paul Edick's remuneration changed compared to Xeris Biopharma Holdings's earnings?
DateTotal Comp.SalaryCompany Earnings
Sep 30 2022n/an/a

-US$133m

Jun 30 2022n/an/a

-US$137m

Mar 31 2022n/an/a

-US$138m

Dec 31 2021US$4mUS$664k

-US$123m

Sep 30 2021n/an/a

-US$94m

Jun 30 2021n/an/a

-US$84m

Mar 31 2021n/an/a

-US$80m

Dec 31 2020US$2mUS$627k

-US$91m

Sep 30 2020n/an/a

-US$102m

Jun 30 2020n/an/a

-US$119m

Mar 31 2020n/an/a

-US$129m

Dec 31 2019US$4mUS$598k

-US$126m

Sep 30 2019n/an/a

-US$113m

Jun 30 2019n/an/a

-US$95m

Mar 31 2019n/an/a

-US$73m

Dec 31 2018US$1mUS$535k

-US$60m

Sep 30 2018n/an/a

-US$49m

Jun 30 2018n/an/a

-US$42m

Mar 31 2018n/an/a

-US$34m

Dec 31 2017US$1mUS$490k

-US$27m

Compensation vs Market: Paul's total compensation ($USD3.76M) is above average for companies of similar size in the US market ($USD1.75M).

Compensation vs Earnings: Paul's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Paul Edick
Chairman & CEO1.5yrsUS$3.76m0.52%
$ 932.4k
John Shannon
President & COO1.08yrsUS$1.73m0.46%
$ 817.0k
Beth Hecht
Chief Legal Officer & Corporate Secretary1.08yrsUS$1.42m0.32%
$ 576.6k
Steven Prestrelski
Co-Founder & Chief Scientific Officer1.08yrsno data0.37%
$ 657.5k
Steven Pieper
Chief Financial Officer1.08yrsno data0.040%
$ 71.9k
Allison Wey
Senior Vice President of Investor Relations & Corporate Communications4.33yrsno datano data
Kenneth Johnson
Senior VP of Global Development & Medical Affairs1.08yrsno data0.0051%
$ 9.1k
Kevin McCulloch
Chief Commercial Officerno datano datano data

1.1yrs

Average Tenure

58.5yo

Average Age

Experienced Management: XERS's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Paul Edick
Chairman & CEO1.83yrsUS$3.76m0.52%
$ 932.4k
John Brooks
Scientific Advisory Board Memberno datano datano data
Orville Kolterman
Member of Scientific Advisory Boardno datano datano data
Jeffrey Sherman
Independent Director1.08yrsUS$73.07k0.037%
$ 66.5k
John Schmid
Lead Independent Director1.08yrsUS$105.07k0.0042%
$ 7.5k
Garheng Kong
Independent Non-Executive Director1.08yrsUS$41.02k0.037%
$ 66.2k
W. Ward
Member of Scientific Advisory Boardno datano datano data
Marla Persky
Independent Director1.08yrsUS$79.07k0%
$ 0
Morey Haymond
Scientific Advisory Board Memberno datano datano data
John Johnson
Independent Non-Executive Director1.08yrsUS$40.06k0.35%
$ 631.4k
Barbar-Jean Bormann-Kennedy
Independent Director1.08yrsUS$79.07k0%
$ 0
Dawn Halkuff
Independent Director1.08yrsUS$73.07k0%
$ 0

1.1yrs

Average Tenure

65yo

Average Age

Experienced Board: XERS's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.